NCT06208033 is a EARLY_PHASE1 clinical trial of SMET12 in EGFR Positive Non-small Cell Lung Cancer, sponsored by Fujian Cancer Hospital.

Who is sponsoring NCT06208033?

NCT06208033 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT06208033?

Interventions in NCT06208033: SMET12, SMET12, SMET12.

What condition does NCT06208033 study?

NCT06208033 studies EGFR Positive Non-small Cell Lung Cancer.

Is NCT06208033 still recruiting?

NCT06208033 is currently status unknown. Last updated 17 January 2024.

Last reviewed 2024-01-17 · How we verify

NCT06208033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Status unknown EARLY_PHASE1 Last updated 17 January 2024

What this trial tests

EARLY_PHASE1 trial testing SMET12 in EGFR Positive Non-small Cell Lung Cancer in 40 participants. Status unknown.

Timeline

10 January 2024

Primary endpoint
20 October 2024

30 December 2024

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	10 January 2024
Primary completion	20 October 2024
Estimated completion	30 December 2024
Sites	1 location across China

Drugs / interventions tested

SMET12 — full drug profile →
SMET12 — full drug profile →
SMET12 — full drug profile →

Conditions studied

EGFR Positive Non-small Cell Lung Cancer — all drugs for EGFR Positive Non-small Cell Lung Cancer →

Sponsor

Fujian Cancer Hospital

Who can join

18 and older, any sex, with EGFR Positive Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.
Wang Z, Song Y, Wang A, Liu B. · · 2026 · PMID 42100320 · DOI 10.3389/fphar.2026.1795614
Emerging Immunotherapy and Antibody-Derived Therapeutics for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Review.
Hou AY, Elantably D, Manochakian R, Velcheti V, et al · · 2026 · PMID 42073614 · DOI 10.3390/cancers18081291
Efficacy and safety of SMET12 in combination with toripalimab and chemotherapy in advanced non-small-cell lung cancer patients tested positive for EGFR protein who are treatment-naïve or harbor acquired resistance to standard therapy: a phase 2, multi-cohort clinical trial.
Lin J, Chen S, Li M, Weng L, et al · · 2025 · PMID 41583476 · DOI 10.3389/fimmu.2025.1706961

Verify or expand the search:

Other recruiting trials for EGFR Positive Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT04900935 — Patient-centered, Optimal Integration of Survivorship and Palliative Care · NA · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06208033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 17 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06208033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing